PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Oxybutynin - Overactive bladder (adults)

PAD Profile : Oxybutynin - Overactive bladder (adults)

Keywords :
OAB, urinary frequency, urge incontinence, urinary incontinence, LUTS, anticholinergics, antimuscarinics
Brand Names Include :
Cystrin, Ditropan, Lyrinel XL

Traffic Light Status

Status 1 of 3.

Status :
Green (see narrative)
Important
Formulations :
  • Patches
Important Information :
Solifenacin 1mg/ml oral SUSPENSION is preferred for patients with swallowing difficulties. Oxybutynin patches are reserved for patients where an oral formulation is not suitable
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 3.

Status :
Non Formulary
Important
Formulations :
  • Modified release tablets
  • Oral solution
  • Tablets
Important Information :
Switch to solifenacin recommended (if appropriate).
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Status 3 of 3.

Status :
N/A
Formulations :
  • Intravesical
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :

This drug/device has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.

05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Oxybutynin immediate-release and modified-release tablets are non-formulary. A switch from oxybutinin tablets to solifenacin is recommended (where appropriate).

Patients with swallowing difficulties

Solifenacin oral SUSPENSION 1mg/ml sugar free is the preferred treatment option.

Oxybutynin patches should be reserved for patients in whom an oral route is not suitable. 

See Selection Tool for locally agreed OAB treatment options

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More